| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-09-25 | Novo Nordisk (Denmark) | obesity | Metabolic diseases | Construction of a production plant | ||
| 2014-09-25 | Pharmacyclics (USA - CA) Servier (France) | pan-HDAC inhibitor compounds involving abexinostat | termination of an R&D agreement |
Cancer - Oncology | Termination of an agreement | |
| 2014-09-25 | Epirus Biopharmaceuticals (USA - MA) Livzon Mabpharm (China) | up to five biosimilar products including Epirus\' Remicade® biosimilar BOW015 | development production manufacturing commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Development agreement | |
| 2014-09-24 | Paion (Germany) Yichang Humanwell Pharmaceutical (China) | Morphine-6-glucuronide (M6G) | peri-operative pain | licensing |
CNS diseases | Licensing agreement |
| 2014-09-24 | Sigma-Aldrich\'s SAFC (USA - MO) Baxter (USA - IL) | antibody drug conjugates, drug linkers | Technology - Services | Production agreement | ||
| 2014-09-24 | Genzyme (USA - MA), a Sanofi company (France) University of Florida (USA - Fl) University of Pennsylvania (USA - PA) | gene therapy for Leber congenital amaurosis type 1 (LCA-1) | Leber congenital amaurosis type 1 (LCA-1) | Rare diseases - Genetic diseases - Ophtalmological diseases | R&D agreement | |
| 2014-09-23 | Rhizen Pharmaceuticals (Switzerland) TG Therapeutics (USA - NY) | selective PI3K delta kinase inhibitors, including RP5264 and backup molecules | haematological cancers, autoimmune diseases | joint-venture |
Cancer - Oncology - Autoimmune diseases | Licensing agreement |
| 2014-09-23 | BiogenIdec (USA - MA) | Nomination | ||||
| 2014-09-23 | Transgene (France) | chief scientific officer | nomination | Nomination | ||
| 2014-09-23 | Forma Therapeutics (USA - MA) Moffitt Cancer Center (USA - FL) | histone deacetylases (HDACs), epigenetics | Cancer - Oncology - Immunological diseases | R&D agreement | ||
| 2014-09-23 | Ophthotech (USA - NY) | chief financial officer | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2014-09-23 | Calixar (France) VirPath (France) | manufacturing process for high performance influenza vaccines | influenza | Infectious diseases | Development agreement | |
| 2014-09-23 | BIA (UK) ABPI (UK) | production manufacturing |
Production agreement | |||
| 2014-09-23 | Atara Biotherapeutics (USA - CA) Memorial Sloan Kettering Cancer Center (USA - NY) | allogeneic T-cell therapies | development commercialisation |
Cancer - Oncology - Infectious diseases | Development agreement | |
| 2014-09-22 | Genzyme (USA - MA), a Sanofi company (France) Charcot-Marie-Tooth Association (CMTA) (USA - IL) | small molecule candidate therapies for CMT1A | Charcot-Marie-Tooth disease type 1A (CMT1A) | collaboration - research | Rare diseases - Genetic diseases - Neurological diseases | Collaboration agreement |
| 2014-09-22 | MediGene (Germany) Trianta Immunotherapies (Germany) Max Delbrück Center for Molecular Medicine (MDC) (Germany) Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) (Germany) | immunotherapy platform TABs (T-cell-specific AntiBodies) | Autoimmune diseases - Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2014-09-22 | Abcam (UK) Children’s Cancer Institute (Australia) | multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ | Licensing agreement | |||
| 2014-09-19 | Molecular Partners (Switzerland) | Nomination | ||||
| 2014-09-19 | Genticel (France) | Nomination | ||||
| 2014-09-19 | Oryzon Genomics (Spain) | member of the board of directors | nomination | Cancer - Oncology - Neurodegenerative diseases | Nomination |
